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pared to the $125 million in savings attributed to the Medi-Cal
equivalent NDCs, an additional $8 million could be gained if
repackaged pharmaceuticals were priced with a relevant Medi-
Cal rate such as an average Estimated Acquisition Cost, an
overall savings of 35.8%. On a per prescription basis, the prac-
tice of repackaging costs an additional $20 when compared to a
Medi-Cal pharmacy dispensed reimbursement rate. CONCLU-
SION: This study informs new legislation being proposed to stop
the generous pricing of repackaged pharmaceuticals due to non-
equivalent NDCs. For the ﬁrst time we describe the practice of
repackaging pharmaceuticals and identify cost savings expected
with alternative pricing systems, but also identify the value of
repackaging pharmaceuticals for WC patients.
PPN4
PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO
PATIENT CONTROLLED ANALGESIA
Nuyts G, Jones MP
Johnson and Johnson, Raritan, NJ, USA
OBJECTIVES: Patient controlled analgesia (PCA) with pump
delivery is the mainstay of modern postoperative pain manage-
ment, with often better pain control compared to competing
methods. We performed a data mining study to identify the 
clinical and hospital infrastructure correlates of PCA use.
METHODS: Patients older than 18 years having major opera-
tive procedures expected to require strong opioid based post-
operative pain control were selected from the Premier Perspective
database. Obstetric patients were excluded. Two random
samples were selected: a training sample of N = 21,782 and a
validation sample of N = 21,538. Factor analysis mapped the 75
observed explanatory variables, not related to post-operative
pain method onto 17 independent factors. Patient segmentation
was performed based on cluster analysis. RESULTS: Thirteen
distinct clusters were identiﬁed each with distinguishing demo-
graphic, clinical, payor and hospital setting features. Percent of
PCA use in each of the segments ranged from 3% to 38%. Six
segments, accounting for 3.5%, 1.8%, 8.4%, 4.1%, 6.1% and
9.2% of the total population had PCA usage below 10%. Only
three segments had PCA usage more than 20% with 4.7%,
14.5% and 7.8% of the population. Qualitative evaluation indi-
cated that the primary factor determining whether a segment had
low or high PCA use was the circumstance of admission: for
urgent admissions PCA was lowest, while the highest PCA use
was observed in those segments characterized by elective admis-
sions. CONCLUSION: Use of PCA differs between segments in
a heterogeneous cohort of post-operative pain patients. That the
driver of this difference was admission source may suggest that
time required to prepare PCA is an important factor in its actual
use and that thus easier PCA methods may increase patient’s use
of PCA.
PAIN—Patient Reported Outcomes
PPN5
ADVANCES IN PAIN MEASUREMENT: ITEM RESPONSE
THEORY (IRT) BASED METHODS AND THE PAIN IMPACT
QUESTIONNAIRE (PIQ-6)
Becker J, Saris-Baglama RN, Bjorner JB, Kosinski M,Ware JE
QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To use IRT-based methods to develop a six-item
questionnaire (PIQ-6) measuring pain severity and pain impact.
IRT was used to: 1) identify the most informative items from a
bank of 65 items, 2) evaluate construct validity, 3) norm the PIQ-
6 to the US general population; 4) cross-calibrate it to the SF-
36v2 BP scale; 5) develop a simple scoring approach based on
response category weights matching the IRT score; and 6) build
a computerized version to facilitate monitoring and management
of pain. METHODS: Items analyses and selection were based on
data from two web-based general population samples (n = 782,
n = 829) and a chronic pain patients sample (n = 306). Norming
was achieved by recalibrating the IRT-based item parameter
using 1998 US representative norm data of the SF36v2 (n =
7069). Cross-calibration of the PIQ-6 and SF-36v2 was per-
formed by estimating the expected SF-36v2 BP scale score using
IRT-based item parameter. The PIQ-6 computerized version was
programmed with Microsoft Visual Basic. RESULTS: Six items
were identiﬁed that ﬁtted an unidimensional IRT model, showed
high measurement precision and did not show differential item
functioning. Construct validity was supported by high correla-
tions with other pain measures and strong discrimination of pain
patients and the general population. The PIQ-6 is normed so that
a score of 50 represents the US general population norm (sd =
10). A cross-calibration table of the PIQ-6/SF-36v2 was created
to facilitate communication between researchers using those 
different instruments. The simple hand scoring approach had 
satisfactory agreement with the IRT scores. The PIQ-6 was 
programmed as computerized stand-alone/PDA/online versions
allowing for an easy administration, scoring and immediate feed-
back reporting including interpretation guidelines. CONCLU-
SIONS: Pain measurement can be improved by using IRT and
computerized methods. Noteworthy advantages of the PIQ-6 are
the enhancement of measurement precision and coverage as well
as the facilitation of monitoring and managing pain.
PATIENT-REPORTED OUTCOMES
PRO1
RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL
COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE
DATABASE ANALYSIS
Kochevar JJ1,Williams TD1
1Kochevar Research Associates, Boston MA, USA
OBJECTIVES: Our objective was to examine results of different
calculation methods for compliance, persistence and medication
gaps using prescription reﬁll claims. METHODS: This was a ret-
rospective analysis of statin prescription claims in the Protocare
database from 1/1/96 to 12/31/02. Statistics were based on ﬁrst-
time statin users (no statin claims in last year) continuously
enrolled for a minimum of 2.5 years after their ﬁrst statin claim
(N = 45,754) and up to a maximum of 6 years. Compliance was
calculated as the “simple” medical possession ratio (MPR)—
days supply/ 365 days—and as “adjusted” MPR, systematically
accounting for gaps and surplus days supply. Persistence was cal-
culated as “continuous” statin persistence (no gap in supply
greater than 30 days) and as “any” statin supply per one year
periods. Gaps were calculated for number of gaps of one day or
more without days supply and average gap length in 365 days.
RESULTS: “Simple” MPR in the ﬁrst year of use was 62% (S.D.
= 0.36). For the same period “adjusted” MPR was 59% (S.D.
0.33) and lower for 50% of the sample. The average difference
was 0.04 (14.6 days). Approximately 34% of the sample was
continuously persistent thru year 1, falling to 21% in year 2;
however, 73 percent had at least one prescription in year 2. Com-
pliance, persistence and gaps varied year by year over patient’s
total coverage periods. CONCLUSIONS: Failure to account 
for gaps and cumulative surpluses in prescription reﬁlls can
distort compliance estimates. “Any” persistence statistics indi-
cate that a higher proportion of statin users remain intermittent
rather than discontinued over long periods of time. Statistics on
number and length of gaps are necessary to provide a full
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description of statin use in reﬁll claims data. DISCLOSURE:
Pﬁzer Inc. provided access to the Protocare database and ﬁnan-
cial support for drawing the initial sample. Kochevar and
Williams have received past support from Pﬁzer Inc. but not for
this analysis.
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SELF-REPORTED HEALTH STATUS PREDICTORS OF
MEDICATION ADHERENCE IN OLDER ADULTS WITH
CHRONIC DISEASES
Balkrishnan R1, Jayawant SS1, Bhosle MJ1,Anderson RT2
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2Wake Forest University School of Medicine, Winston Salem,
NC, USA
OBJECTIVE: Medication adherence is a recognized problem in
older persons and is exacerbated by the factors such as comor-
bid conditions. The aim of this study was to examine the rela-
tionship between self-reported health status and medication
adherence in older adults with chronic diseases. METHODS: A
longitudinal cohort study was conducted in older adults (aged
greater than or equal to 65 years) enrolled in a health mainte-
nance organization. Study sample included patient cohorts with
four major chronic diseases: Type 2 Diabetes Mellitus (n = 667),
Overactive Bladder (n = 176), Asthma (n = 129), and Psoriasis
(n = 63). Self-reported health perception, falls, lifestyle, and
depressive symptomatology in the pre-enrollment year were mea-
sured using a risk-assessment questionnaire. The SF-12 ques-
tionnaire assessed the quality of life and the short-form Center
for Epidemiologic Studies Depression Scale assessed depression
level (0–100). Medication Possession Ratio (MPR) was used as
a measure of medication adherence. Multivariate regression
analyses were conducted examining predictors of MPR scores.
RESULTS: A 0.28-point increase in MPR [Range 0–1] was found
in patients receiving oral antidiabetics as compared to patients
who did not receive oral antidiabetics (p < 0.001). Increased
number of comorbidities were associated with decreased adher-
ence (p < 0.05). In OAB patients, previous year hospitalization
was associated with 0.05-point decrease in MPR for antimus-
carinic medication (p < 0.05). For asthmatic patients, depressive
symptomatology was associated with 0.31-point decrease in
MPR (p < 0.05). Psoriasis patients with depressive symptoms and
those whose physical activity was only moderate were less adher-
ent to topical corticosteroids (both p < 0.01). CONCLUSION:
Signiﬁcant associations were found between predictors of health
status such as depressive symptoms and decreased medication
adherence in elderly patients with chronic diseases. Health status
assessments completed at the time of enrollment may have the
potential to identify older adults at risk for poor adherence for
better intervention.
PRO3
EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE
WITH PEGYLATED INTERFERON THERAPY:A PROPENSITY
SCORE MATCHED RETROSPECTIVE COHORT ANALYSIS
Hussein M1, Benner JS1, Lee DW2, Sesti AMS3, Battleman DS1
1ValueMedics Research, LLC, Falls Church,VA, USA, 2GE Healthcare,
Waukesha, WI, USA, 3NDCHealth, Deerﬁeld, IL, USA
OBJECTIVES: Poor adherence to antiviral therapy in hepatitis
C virus (HCV) patients is a well-documented problem. The Be
In Charge® program (BIC) is a comprehensive patient support
program that encourages adherence by providing 24-hour
inbound and proactive outbound telephone nursing support and
mailings of HCV educational materials throughout therapy. The
purpose was to determine the impact of BIC on patient 
adherence to peginterferon alfa-2b combination therapy (peg-
2b). METHODS: A retrospective cohort analysis compared BIC
enrollees to propensity-score matched peg-2b starters not
enrolled in BIC (controls). Subjects were included if they were
≥18 years of age; started peg-2b on or after January 1, 2004;
and could be observed for at least 12 weeks after treatment ini-
tiation. Adherence was measured as the number of injections dis-
pensed and proportion of patients who received an average of
≥1 injection per week during follow-up. Adherence was com-
pared using paired chi-square and t-test. RESULTS: After match-
ing, each cohort consisted of 780 eligible subjects observable 
for ≥12 weeks; 638 and 333 subjects in each cohort were 
observable for 24 and 48 weeks, respectively. BIC subjects
reﬁlled 1.2 more injections (95% conﬁdence interval [CI] 0.52,
1.83; P < 0.0001) than the control cohort within 12 weeks, 2.7
more (95% CI 1.5, 3.8; P < 0.0001) within 24 weeks, and 6.7
more (95% CI 4.3, 9.1; P < 0.0001) within 48 weeks. Addi-
tionally, BIC enrollees were more likely to reﬁll ≥12 injections
within 12 weeks of initiation (72% vs. 64%, P = 0.0005), ≥24
injections within 24 weeks (52% vs. 41%, P < 0.0001), and ≥48
injections within 48 weeks (22% vs. 13%, P = 0.0020). CON-
CLUSION: This quasi-experimental study suggest the BIC
program signiﬁcantly improved adherence to peg-2b. Additional
research is needed to ascertain which aspects of the program are
most effective and which patients are most likely to beneﬁt from
this intervention.
PRO4
PREVALENCE OF MEDICATION COMPLIANCE AND
PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED
CARE POPULATION
Fuldeore M1, Khandelwal NG2, Gams EL1, Sauer T1, Lee KY1
1Walgreens Health Services, Deerﬁeld, IL, USA, 2Auburn University,
Auburn, AL, USA
OBJECTIVES: The primary objective of this project is to assess
the prevalence of medication compliance and persistency with
specialty medications in patients newly diagnosed with speciﬁc
disease conditions such as Growth Hormone (GH), Chronic
Hepatitis C (CHC), Multiple Sclerosis (MS) and Rheumatoid
Arthritis (RA). METHODS: For each disease condition, separate
cohorts of patients who were newly diagnosed between May 1,
2004 and August 1, 2004 time periods were identiﬁed and
selected using PBM pharmacy claims database. Patients were
deﬁned as new to therapy if they were not prescribed the same
specialty medication six months prior to the study period.
Patients who lost prescription drug beneﬁt eligibility during the
study period were excluded from analysis. Identiﬁed patients
were then followed for a period of 12 months from the treat-
ment start date. Compliance was measured by computing the
Medication Possession Ratio (MPR), which is deﬁned as the ratio
of the total days supply obtained to the total number of days in
the study period. Persistency was reported in terms of average
length of therapy in days. The compliance and persistency mea-
sures were also controlled for differences in gender and age.
RESULTS: The mean MPR was 0.66 for patients on GH (N =
60), it was 0.48 for patients on CHC (N = 107, 0.65 on MS (N
= 173) and 0.63 on RA (N = 324). The average length of therapy
for patients on GH was 274. 5 days, on CHC was 196.0, on MS
was 270.1 days and on RA was 285.2 days. CONCLUSIONS:
Non-compliance and non-persistency is a critical and prevalent
problem in the patients taking specialty medications. Disease
speciﬁc efforts are needed to improve medication compliance and
persistency to optimal level in order to achieve effective treat-
ment outcomes.
